nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.02.2004 | Symposium in Writing

Role of IL-13 in regulation of anti-tumor immunity and tumor growth

verfasst von: Masaki Terabe, Jong Myun Park, Jay A. Berzofsky

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Major mediators of anti-tumor immunity are CD4⁺ T_h1 cells and CD8⁺ cytotoxic T lymphocytes (CTLs). In tumor-bearing animals, the T_h1- and CTL-mediated anti-tumor immunity is down-regulated in multiple ways. Better understanding of negative regulatory pathways of tumor immunity is crucial for the development of anti-tumor vaccines and immunotherapies. Since immune deviation toward T_h2 suppresses T_h1 development, it has been thought that induction affecting a T_h2 immune response is one of the mechanisms that down-regulate effective tumor immune responses. Recent studies using T_h2-deficient signal transducer and activator (Stat6) KO mice demonstrated that this hypothesis was the case. IL-13 is one of the T_h2 cytokines that has very similar features to IL-4 through sharing some receptor components and Stat6 signal transduction. It has been thought that IL-13 is not as critical for immune deviation as IL-4 since it cannot directly act on T cells. However, recent studies of IL-13 reveal that this cytokine plays a critical role in many aspects of immune regulation. Studies from our lab and others indicate that IL-13 is central to a novel immunoregulatory pathway in which NKT cells suppress tumor immunosurveillance. Here we will describe biological properties and functions of IL-13, its role in the negative regulation of anti-tumor immunity, and effects of IL-13 on tumor cells themselves.

Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas E, Berzofsky JA (2002) A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. Proc Natl Acad Sci USA 99:13020CrossRefPubMed

Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ (1996) cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J Biol Chem 271:29265CrossRefPubMed

Berzofsky JA, Ahlers JD, Belyakov IM (2001) Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1:209PubMed

Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP (1995) IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 154:799PubMed

Brown KD, Zurawski SM, Mosmann TR, Zurawski G (1989) A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142:679PubMed

Burd PR, Thompson WC, Max EE, Mills FC (1995) Activated mast cells produce interleukin 13. J Exp Med 181:1373PubMed

Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P (1996) Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J Biol Chem 271:16921PubMed

Chaouchi N, Wallon C, Goujard C, Tertian G, Rudent A, Caput D, Ferrera P, Minty A, Vazquez A, Delfraissy JF (1996) Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 87:1022PubMed

Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA (1999) An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104:777PubMed

10.

Chiaramonte MG, Schopf LR, Neben TY, Cheever AW, Donaldson DD, Wynn TA (1999) IL-13 is a key regulatory cytokine for T_h2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 162:920PubMed

11.

Chiaramonte MG, Mentink-Kane M, Jacobson BA, Cheever AW, Whitters MJ, Goad ME, Wong A, Collins M, Donaldson DD, Grusby MJ, Wynn TA (2003) Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med 197:687PubMed

12.

de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, Ait-Yahia S, Banchereau J, Liu YJ, Lebecque S, Caux C (1998) The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 160:1666PubMed

13.

de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, Dang W, Zurawski G, de Vries JE (1993) Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes: comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 151:6370PubMed

14.

Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O’Hara RM Jr, Beier DR, Turner KJ, Wood CR, Collins M (1998) The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161:2317PubMed

15.

Fallon PG, Jolin HE, Smith P, Emson CL, Townsend MJ, Fallon R, McKenzie AN (2002) IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 17:7PubMed

16.

Finkelman FD, Wynn TA, Donaldson DD, Urban JF (1999) The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections. Curr Opin Immunol 11:420

17.

Gabay C, Porter B, Guenette D, Billir B, Arend WP (1999) Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. Blood 93:1299PubMed

18.

Gauchat JF, Schlagenhauf E, Feng NP, Moser R, Yamage M, Jeannin P, Alouani S, Elson G, Notarangelo LD, Wells T, Eugster HP, Bonnefoy JY (1997) A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor. Eur J Immunol 27:971PubMed

19.

Gibbs BF, Haas H, Falcone FH, Albrecht C, Vollrath IB, Noll T, Wolff HH, Amon U (1996) Purified human peripheral blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation. Eur J Immunol 26:2493PubMed

20.

Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB (1998) Requirement for IL-13 independently of IL-4 in experimental asthma [see comments]. Science 282:2261CrossRefPubMed

21.

Hansen DS, Siomos MA, Buckingham L, Scalzo AA, Schofield L (2003) Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. Immunity 18:391PubMed

22.

Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W (2002) Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17:629PubMed

23.

Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Willson TA (1996) Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci USA 93:497CrossRefPubMed

24.

Horohov DW, Crim JA, Smith PL, Siegel JP (1988) IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity. J Immunol 141:4217PubMed

25.

Hoshino T, Winkler-Pickett RT, Mason AT, Ortaldo JR, Young HA (1999) IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma. J Immunol 162:51PubMed

26.

Joshi BH, Kawakami K, Leland P, Puri RK (2002) Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 8:1948PubMed

27.

Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF (2000) Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol 165:6024PubMed

28.

Kanai T, Watanabe M, Hayashi A, Nakazawa A, Yajima T, Okazawa A, Yamazaki M, Ishii H, Hibi T (2000) Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer 82:1717PubMed

29.

Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, Hessel A, Tipsword M, Williams A, Mirtsos C, Itie A, Moyle M, Mak TW (1999) Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189:1939PubMed

30.

Kawakami K, Joshi BH, Puri RK (2000) Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain. Hum Gene Ther 11:1829PubMed

31.

Kawakami M, Leland P, Kawakami K, Puri RK (2000) Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res 12:459PubMed

32.

Kawakami K, Husain SR, Bright RK, Puri RK (2001) Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther 8:861PubMed

33.

Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK (2001) In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 194:1743PubMed

34.

Keegan AD, Nelms K, White M, Wang LM, Pierce JH, Paul WE (1994) An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell 76:811PubMed

35.

Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD (2003) Interleukin-4 and interleukin-13 signaling connections maps. Science 300:1527PubMed

36.

Kindler V, Matthes T, Jeannin P, Zubler RH (1995) Interleukin-2 secretion by human B lymphocytes occurs as a late event and requires additional stimulation after CD40 cross-linking. Eur J Immunol 25:1239PubMed

37.

Kobayashi M, Kobayashi H, Pollard RB, Suzuki F (1998) A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160:5869PubMed

38.

Lebel-Binay S, Laguerre B, Quintin-Colonna F, Conjeaud H, Magazin M, Miloux B, Pecceu F, Caput D, Ferrara P, Fradelizi D (1995) Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol 25:2340PubMed

39.

Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA (2001) Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 194:809CrossRefPubMed

40.

Li H, Sim TC, Alam R (1996) IL-13 released by and localized in human basophils. J Immunol 156:4833PubMed

41.

Lutz MB, Schnare M, Menges M, Rossner S, Rollinghoff M, Schuler G, Gessner A (2002) Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol 169:3574PubMed

42.

Manna SK, Aggarwal BB (1998) IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis. J Immunol 161:2863PubMed

43.

Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky J (1999) A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 163:184PubMed

44.

McKenzie AN (2000) Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13. Pharmacol Ther 88:143PubMed

45.

McKenzie AN, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, Menon S et al (1993) Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 90:3735PubMed

46.

McKenzie AN, Li X, Largaespada DA, Sato A, Kaneda A, Zurawski SM, Doyle EL, Milatovich A, Francke U, Copeland NG et al (1993) Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 150:5436PubMed

47.

Miloux B, Laurent P, Bonnin O, Lupker J, Caput D, Vita N, Ferrara P (1997) Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS Lett 401:163PubMed

48.

Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B et al (1993) Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248PubMed

49.

Morgan JG, Dolganov GM, Robbins SE, Hinton LM, Lovett M (1992) The selective isolation of novel cDNAs encoded by the regions surrounding the human interleukin 4 and 5 genes. Nucleic Acids Res 20:5173PubMed

50.

Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17:701CrossRefPubMed

51.

Obiri NI, Debinski W, Leonard WJ, Puri RK (1995) Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 270:8797PubMed

52.

Ostrand-Rosenberg S, Grusby MJ, Clements VK (2000) Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 165:6015PubMed

53.

Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky J, Dissanayake SK (2002) Resistance to metastatic disease in Stat6-deficient mice requires hematopoietic and non-hematopoietic cells and is IFNγ-dependent. J Immunol 169:5796PubMed

54.

Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G (1998) Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 161:5821PubMed

55.

Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, Foster PS, Rothenberg ME (2001) IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 108:594PubMed

56.

Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, de Waal Malefyt R, de Vries JE (1993) Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 90:3730PubMed

57.

Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T (1999) T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 189:803PubMed

58.

Schuler T, Kammertoens T, Preiss S, Debs P, Noben-Trauth N, Blankenstein T (2001) Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells. J Exp Med 194:1767PubMed

59.

Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, Patterson B, Snow BE, Mak TW (2001) Interleukin 13 and interleukin 13 receptor are frequently expressed by hodgkin and reed-sternberg cells of hodgkin lymphoma. Blood 97:250CrossRefPubMed

60.

Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, Mak TW (2002) Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99:618PubMed

61.

Skinnider BF, Kapp U, Mak TW (2002) The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 43:1203PubMed

62.

Smirnov DV, Smirnova MG, Korobko VG, Frolova EI (1995) Tandem arrangement of human genes for interleukin-4 and interleukin-13: resemblance in their organization. Gene 155:277PubMed

63.

Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661CrossRefPubMed

64.

Spits H, Yssel H, Paliard X, Kastelein R, Figdor C, de Vries JE (1988) IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 141:29PubMed

65.

Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, Nishioka K, Iwamoto I, Taniguchi M (1995) Selective reduction of T cells bearing invariant V alpha 24 J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med 182:1163PubMed

66.

Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA (2000) NKT cell-mediated repression of tumour immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:515PubMed

67.

Terabe M, Matsui S, Park J-M, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA (2003) TGF-b productin and myeloid cells are an effector mechanism through which CD1d-restricted T cells block CTL-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med (in press)

68.

Urban JF Jr, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, Collins M, Finkelman FD (1998) IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 8:255PubMed

69.

Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD (1998) Interleukin-13: central mediator of allergic asthma [see comments]. Science 282:2258CrossRefPubMed

70.

Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, Strominger JL, Hafler DA (1998) Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391:177PubMed

71.

Wood N, Whitters MJ, Jacobson BA, Witek J, Sypek JP, Kasaian M, Eppihimer MJ, Unger M, Tanaka T, Goldman SJ, Collins M, Donaldson DD, Grusby MJ (2003) Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med 197:703PubMed

72.

Wynn TA (2003) IL-13 effector functions. Annu Rev Immunol 21:425PubMed

73.

Yokota T, Otsuka T, Mosmann T, Banchereau J, DeFrance T, Blanchard D, De Vries JE, Lee F, Arai K (1986) Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. Proc Natl Acad Sci USA 83:5894

74.

Zeng D, Lee MK, Tung J, Brendolan A, Strober S (2000) Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol 164:5000PubMed

75.

Zhang JG, Hilton DJ, Willson TA, McFarlane C, Roberts BA, Moritz RL, Simpson RJ, Alexander WS, Metcalf D, Nicola NA (1997) Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J Biol Chem 272:9474CrossRefPubMed

76.

Zurawski G, de Vries JE (1994) Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19PubMed

77.

Zurawski SM, Vega F Jr, Huyghe B, Zurawski G (1993) Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. Embo J 12:2663PubMed

78.

Zurawski SM, Chomarat P, Djossou O, Bidaud C, McKenzie AN, Miossec P, Banchereau J, Zurawski G (1995) The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 270:13869PubMed

Titel: Role of IL-13 in regulation of anti-tumor immunity and tumor growth
verfasst von: Masaki Terabe
Jong Myun Park
Jay A. Berzofsky
Publikationsdatum: 01.02.2004
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2004
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0445-0

Springer Medizin

Role of IL-13 in regulation of anti-tumor immunity and tumor growth

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2004

Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma

Derangement of immune responses by myeloid suppressor cells

Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells

In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein

T-cell responses to multiple antigens presented by RNA-transfected APCs: a possible immunomonitoring tool

Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie